153 related articles for article (PubMed ID: 38441840)
1. Prognostic value of cerebrospinal fluid tumor cell count in leptomeningeal disease from solid tumors.
Barbour AB; Blouw B; Taylor LP; Graber JJ; McGranahan T; Blau M; Halasz LM; Lo SS; Tseng YD; Venur V; Yang JT
J Neurooncol; 2024 May; 167(3):509-514. PubMed ID: 38441840
[TBL] [Abstract][Full Text] [Related]
2. Keeping a track on leptomeningeal disease in non-small cell lung cancer: A single-institution experience with CNSide
Puri S; Malani R; Chalmers A; Kerrigan K; Patel SB; Monynahan K; Cannon L; Blouw B; Akerley W
Neurooncol Adv; 2024; 6(1):vdad150. PubMed ID: 38196737
[TBL] [Abstract][Full Text] [Related]
3. Diagnosis of Leptomeningeal Metastasis in Women With Breast Cancer Through Identification of Tumor Cells in Cerebrospinal Fluid Using the CNSide™ Assay.
Wooster M; McGuinness JE; Fenn KM; Singh VM; Franks LE; Lee S; Cieremans D; Lassman AB; Hershman DL; Crew KD; Accordino MK; Trivedi MS; Iwamoto F; Welch MR; Haggiagi A; Schultz RD; Huynh L; Sales E; Fisher D; Mayer JA; Kreisl T; Kalinsky K
Clin Breast Cancer; 2022 Jun; 22(4):e457-e462. PubMed ID: 34920954
[TBL] [Abstract][Full Text] [Related]
4. The HER2 flip-HER2 amplification of tumor cells in the cerebrospinal fluid of breast cancer patients with leptomeningeal disease: implications for treating the LM tumor with anti-HER2 therapy.
Kumthekar PU; Blouw B; Corkos P; Nagpal S; Tripathy A; Piccioni D; Youssef M
Front Oncol; 2024; 14():1402651. PubMed ID: 38826788
[TBL] [Abstract][Full Text] [Related]
5. Detection of Leptomeningeal Disease Using Cell-Free DNA From Cerebrospinal Fluid.
White MD; Klein RH; Shaw B; Kim A; Subramanian M; Mora JL; Giobbie-Hurder A; Nagabhushan D; Jain A; Singh M; Kuter BM; Nayyar N; Bertalan MS; Stocking JH; Markson SC; Lastrapes M; Alvarez-Breckenridge C; Cahill DP; Gydush G; Rhoades J; Rotem D; Adalsteinsson VA; Mahar M; Kaplan A; Oh K; Sullivan RJ; Gerstner E; Carter SL; Brastianos PK
JAMA Netw Open; 2021 Aug; 4(8):e2120040. PubMed ID: 34369989
[TBL] [Abstract][Full Text] [Related]
6. Clinicopathological and Treatment-Associated Prognostic Factors in Patients with Breast Cancer Leptomeningeal Metastases in Relation to Tumor Biology.
Griguolo G; Pouderoux S; Dieci MV; Jacot W; Bourgier C; Miglietta F; Firmin N; Conte P; Viala M; Guarneri V; Darlix A
Oncologist; 2018 Nov; 23(11):1289-1299. PubMed ID: 30120164
[TBL] [Abstract][Full Text] [Related]
7. Quantitative assessment of circulating tumor cells in cerebrospinal fluid as a clinical tool to predict survival in leptomeningeal metastases.
Diaz M; Singh P; Kotchetkov IS; Skakodub A; Meng A; Tamer C; Young RJ; Reiner AS; Panageas KS; Ramanathan LV; Pentsova E
J Neurooncol; 2022 Mar; 157(1):81-90. PubMed ID: 35113288
[TBL] [Abstract][Full Text] [Related]
8. Cerebrospinal fluid circulating tumor cells: a novel tool to diagnose leptomeningeal metastases from epithelial tumors.
Lin X; Fleisher M; Rosenblum M; Lin O; Boire A; Briggs S; Bensman Y; Hurtado B; Shagabayeva L; DeAngelis LM; Panageas KS; Omuro A; Pentsova EI
Neuro Oncol; 2017 Sep; 19(9):1248-1254. PubMed ID: 28821205
[TBL] [Abstract][Full Text] [Related]
9. Comparison of CSF cytology and spinal magnetic resonance imaging in the detection of leptomeningeal disease in pediatric medulloblastoma or primitive neuroectodermal tumor.
Fouladi M; Gajjar A; Boyett JM; Walter AW; Thompson SJ; Merchant TE; Jenkins JJ; Langston JW; Liu A; Kun LE; Heideman RL
J Clin Oncol; 1999 Oct; 17(10):3234-7. PubMed ID: 10506624
[TBL] [Abstract][Full Text] [Related]
10. Integration of rare cell capture technology into cytologic evaluation of cerebrospinal fluid specimens from patients with solid tumors and suspected leptomeningeal metastasis.
Torre M; Lee EQ; Chukwueke UN; Nayak L; Cibas ES; Lowe AC
J Am Soc Cytopathol; 2020; 9(1):45-54. PubMed ID: 31606331
[TBL] [Abstract][Full Text] [Related]
11. Comparison of lumbar and shunt cerebrospinal fluid specimens for cytologic detection of leptomeningeal disease in pediatric patients with brain tumors.
Gajjar A; Fouladi M; Walter AW; Thompson SJ; Reardon DA; Merchant TE; Jenkins JJ; Liu A; Boyett JM; Kun LE; Heideman RL
J Clin Oncol; 1999 Jun; 17(6):1825-8. PubMed ID: 10561221
[TBL] [Abstract][Full Text] [Related]
12. Predictors of survival in metastatic melanoma patients with leptomeningeal disease (LMD).
Ferguson SD; Bindal S; Bassett RL; Haydu LE; McCutcheon IE; Heimberger AB; Li J; O'Brien BJ; Guha-Thakurta N; Tetzlaff MT; Tawbi H; Davies MA; Glitza IC
J Neurooncol; 2019 May; 142(3):499-509. PubMed ID: 30847840
[TBL] [Abstract][Full Text] [Related]
13. Prognostic impact of clinical and radiological factors on leptomeningeal metastasis from solid cancers.
Nakagawa K; Takano K; Nishino K; Ohe S; Nakayama T; Arita H
J Neurooncol; 2024 May; 167(3):397-406. PubMed ID: 38430420
[TBL] [Abstract][Full Text] [Related]
14. Leptomeningeal carcinomatosis: prognostic value of clinical, cerebrospinal fluid, and neuroimaging features.
Palma JA; Fernandez-Torron R; Esteve-Belloch P; Fontes-Villalba A; Hernandez A; Fernandez-Hidalgo O; Gallego Perez-Larraya J; Martinez-Vila E
Clin Neurol Neurosurg; 2013 Jan; 115(1):19-25. PubMed ID: 22534095
[TBL] [Abstract][Full Text] [Related]
15. Leptomeningeal disease from melanoma-Poor prognosis despite new therapeutic modalities.
Chorti E; Kebir S; Ahmed MS; Keyvani K; Umutlu L; Kanaki T; Zaremba A; Reinboldt-Jockenhoefer F; Knispel S; Gratsias E; Roesch A; Ugurel S; Scheffler B; Schadendorf D; Livingstone E; Meier F; Glas M; Zimmer L
Eur J Cancer; 2021 May; 148():395-404. PubMed ID: 33789203
[TBL] [Abstract][Full Text] [Related]
16. Risk factors for leptomeningeal carcinomatosis in patients with brain metastases who have previously undergone stereotactic radiosurgery.
Huang AJ; Huang KE; Page BR; Ayala-Peacock DN; Lucas JT; Lesser GJ; Laxton AW; Tatter SB; Chan MD
J Neurooncol; 2014 Oct; 120(1):163-9. PubMed ID: 25048529
[TBL] [Abstract][Full Text] [Related]
17. The value of tandem CSF/MRI evaluation for predicting disseminated disease in childhood central nervous system neoplasms.
Pang J; Banerjee A; Tihan T
J Neurooncol; 2008 Mar; 87(1):97-102. PubMed ID: 17987260
[TBL] [Abstract][Full Text] [Related]
18. Treatment and prognosis of leptomeningeal disease secondary to metastatic breast cancer: A single-centre experience.
Kingston B; Kayhanian H; Brooks C; Cox N; Chaabouni N; Redana S; Kalaitzaki E; Smith I; O'Brien M; Johnston S; Parton M; Noble J; Stanway S; Ring A; Turner N; Okines A
Breast; 2017 Dec; 36():54-59. PubMed ID: 28968585
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic and prognostic significance of flow cytometry immunophenotyping in patients with leptomeningeal carcinomatosis.
Subirá D; Simó M; Illán J; Serrano C; Castañón S; Gonzalo R; Granizo JJ; Martínez-García M; Navarro M; Pardo J; Bruna J
Clin Exp Metastasis; 2015 Apr; 32(4):383-91. PubMed ID: 25795393
[TBL] [Abstract][Full Text] [Related]
20. Genomic and transcriptomic correlates of immunotherapy response within the tumor microenvironment of leptomeningeal metastases.
Prakadan SM; Alvarez-Breckenridge CA; Markson SC; Kim AE; Klein RH; Nayyar N; Navia AW; Kuter BM; Kolb KE; Bihun I; Mora JL; Bertalan MS; Shaw B; White M; Kaplan A; Stocking JH; Wadsworth MH; Lee EQ; Chukwueke U; Wang N; Subramanian M; Rotem D; Cahill DP; Adalsteinsson VA; Miller JW; Sullivan RJ; Carter SL; Brastianos PK; Shalek AK
Nat Commun; 2021 Oct; 12(1):5955. PubMed ID: 34642316
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
